[{"id":"be5c7d1d-dede-47c6-9803-529770521936","acronym":"IMM-101-015","url":"https://clinicaltrials.gov/study/NCT03711188","created_at":"2021-01-18T18:11:38.254Z","updated_at":"2024-07-02T16:35:07.136Z","phase":"Phase 2","brief_title":"A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma","source_id_and_acronym":"NCT03711188 - IMM-101-015","lead_sponsor":"Immodulon Therapeutics Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 12/02/2021","primary_completion_date":" 12/02/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2024-04-29"},{"id":"2e930a93-29d9-4e74-86ca-70d69ff2822c","acronym":"ANTONIO","url":"https://clinicaltrials.gov/study/NCT05118724","created_at":"2021-11-12T13:53:33.926Z","updated_at":"2024-07-02T16:35:25.018Z","phase":"Phase 2","brief_title":"Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin","source_id_and_acronym":"NCT05118724 - ANTONIO","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • oxaliplatin • IMM-101"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/10/2021","start_date":" 12/10/2021","primary_txt":" Primary completion: 11/15/2026","primary_completion_date":" 11/15/2026","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2023-12-28"},{"id":"6330501d-072a-4936-ac96-9ddc79c3045a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01539824","created_at":"2021-01-18T06:30:18.738Z","updated_at":"2024-07-02T16:37:27.310Z","phase":"Phase 2","brief_title":"A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer","source_id_and_acronym":"NCT01539824","lead_sponsor":"Immodulon Therapeutics Ltd","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMM-101"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2016-12-02"}]